Market Scenario
Global Preclinical imaging market is projected to attain a market valuation of US$ 3,011.7 million by 2031, growing at a CAGR of 5.6% during period 2023-2031. The market was valued at US$ 1,873.6 million in 2022.
The growth of the preclinical imaging market can be attributed to several factors, including the increasing demand for non-invasive imaging techniques. Preclinical imaging provides non-invasive techniques that enable visualization and measurement of biological processes, making it an attractive alternative to invasive procedures. The market is also witnessing significant advancements in imaging technologies such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) imaging, which have improved the accuracy and resolution of preclinical imaging.
The rising prevalence of chronic diseases is also driving the demand for preclinical imaging for disease diagnosis, monitoring, and treatment. Moreover, the increasing investments in preclinical research, particularly in the pharmaceutical and biotechnology industries, are driving the demand for preclinical imaging technologies to support drug discovery and development. Finally, government initiatives, such as funding programs and regulatory support for preclinical imaging technologies, are also expected to drive market growth. In conclusion, the preclinical imaging market is expected to continue its growth trajectory over the forecast period, driven by these various factors.
Market Dynamics
Drivers:
Increasing Demand for Non-Invasive Imaging Techniques
Non-invasive imaging techniques are becoming increasingly popular in the healthcare industry due to their ability to visualize and measure biological processes without the need for invasive procedures. This has led to an increase in demand for preclinical imaging, which provides non-invasive techniques for disease diagnosis, monitoring, and treatment. In addition, preclinical imaging can also be used for preclinical research, drug development, and toxicology studies, further driving the demand for these technologies. The non-invasive nature of preclinical imaging has several advantages, including reduced risks to patients, faster recovery times, and lower healthcare costs. As a result, the demand for non-invasive imaging techniques is expected to continue to drive the growth of the preclinical imaging market.
Advancements in Preclinical Imaging Technologies
The preclinical imaging market is witnessing significant advancements in imaging technologies, such as MRI, CT, PET, and optical imaging. These advancements have led to improved imaging quality, resolution, and sensitivity, making preclinical imaging a more reliable tool for research and development. The development of new and improved imaging modalities, such as multimodal imaging, molecular imaging, and functional imaging, has also expanded the scope of preclinical imaging applications. For example, molecular imaging allows for the visualization of molecular and cellular processes, while functional imaging allows for the study of physiological processes in real-time. As a result, the advancements in preclinical imaging technologies are expected to continue to drive market growth by expanding the range of applications and improving the accuracy of preclinical imaging.
Restraint:
Regulatory Challenges
One of the main restraints on the growth of the preclinical imaging market is the regulatory challenges associated with preclinical research. Regulatory authorities, such as the US FDA and the European Medicines Agency, require that preclinical studies meet specific guidelines and standards before they can be used for drug development and approval. This can make it difficult for companies to conduct preclinical studies, as they must navigate complex regulatory frameworks and obtain regulatory approval for their studies. In addition, the regulatory requirements for preclinical studies can vary between countries and regions, leading to further challenges for companies that operate globally. As a result, regulatory challenges can be a significant restraint on the growth of the preclinical imaging market.
Segmental Analysis
By Type:
The preclinical imaging market can be segmented by type into product and services. The product segment is expected to capture more than 67% of the market share during the forecast period. This is due to the high demand for preclinical imaging products such as MRI, CT, PET, and optical imaging, among others, for research and development activities in the pharmaceutical and biotechnology industries. Preclinical imaging products are used for visualizing and measuring biological processes in animal models in the early stages of drug development. These imaging products help researchers to identify and quantify biomarkers, evaluate drug efficacy, and study disease progression. The demand for preclinical imaging products is also driven by the increasing need for non-invasive imaging technologies for disease diagnosis, monitoring, and treatment.
By Product:
The preclinical imaging market can be segmented by product into MRI, CT, PET, ultrasound imaging, optical imaging, and others. Among these, ultrasound imaging is expected to dominate the market with more than 25% market share during the forecast period. This is due to the non-invasive nature of ultrasound imaging, its cost-effectiveness, and its ability to provide real-time imaging.
Ultrasound imaging is widely used for research and development activities in the preclinical imaging market, particularly for cardiovascular research, cancer research, and developmental biology. Additionally, the increasing adoption of high-frequency ultrasound imaging and 3D ultrasound imaging technologies is expected to further drive the growth of this segment.
By Application:
The preclinical imaging market can be segmented by application into research and development, disease diagnosis, and drug development. Research and development is expected to dominate the market with more than 58% market share during the forecast period. This is due to the increasing demand for preclinical imaging technologies for research and development activities in the pharmaceutical and biotechnology industries. Preclinical imaging is used in the early stages of drug development to visualize and measure biological processes, allowing researchers to evaluate the safety and efficacy of new drugs.
In addition, preclinical imaging is also used for disease modeling, biomarker discovery, and target identification. The increasing investment in preclinical research, particularly in the pharmaceutical and biotechnology industries, is expected to drive the demand for preclinical imaging technologies for research and development activities.
By End User
The preclinical imaging market can also be segmented by end user, which includes pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations. Among these, biotech companies are expected to dominate the market with more than 45% market share during the forecast period. This dominance can be attributed to the increasing investment in research and development activities by biotech companies, particularly in the areas of drug discovery and development. Biotech companies are focused on developing new drugs and therapies for a variety of diseases and disorders, and preclinical imaging plays a crucial role in the early stages of drug development.
Preclinical imaging technologies help biotech companies to visualize and measure biological processes in animal models, evaluate drug efficacy, and study disease progression. These technologies in the global preclinical imaging market also aid in identifying and quantifying biomarkers, which are used to develop new drugs and therapies.
Regional Analysis
North America is expected to be the dominant market for preclinical imaging during the forecast period, accounting for over 43% of the global market share. This can be attributed to several factors, including the presence of a well-established research and development infrastructure in the region. With some of the world's largest pharmaceutical and biotechnology companies based in the United States, there is a high demand for preclinical imaging technologies in North America. Additionally, the region has a highly developed healthcare system that emphasizes the use of advanced medical technologies, leading to a high demand for preclinical imaging for disease diagnosis, monitoring, and treatment. The prevalence of chronic diseases, such as cancer and cardiovascular diseases, in the region further drives the demand for preclinical imaging technologies.
Furthermore, the high level of investment in research and development activities in North America is another factor contributing to the region's dominance in the preclinical imaging market. The US government invests significantly in research and development activities in the healthcare industry, including preclinical imaging. This investment is expected to drive the development and adoption of new and improved preclinical imaging technologies, leading to continued growth of the market in North America.
List of Key Companies Profiled:
Recent Developments:
Market Segmentation Overview
By Type
By Product
By Application
By End User
By Distribution Channel
By Region
| Report Attribute | Details |
|---|---|
| Market Size Value in 2022 | US$ 1,873.6 Million |
| Expected Revenue in 2031 | US$ 3,011.7 Million |
| Historic Data | 2018-2021 |
| Base Year | 2022 |
| Forecast Period | 2023-2031 |
| Unit | Value (USD Mn) |
| CAGR | 5.6% |
| Segments covered | By Type, By Product, By Application, By End User, By Distribution Channel, By Region |
| Key Companies | Agilent Technologies, Bruker Corporation, Canon, Fujifilm Corporation, General Electric (GE), Hitachi, Ltd., Hologic, Konica Minolta, Inc., Koninklijke Philips, Mediso Limited, MILabs B.V., Molecubes, MR Solutions, PerkinElmer, Incorporated, Siemens Healthineers, TriFoil Imaging, Varex Imaging, Other Prominent Players |
| Customization Scope | Get your customized report as per your preference. Ask for customization |
The main goals of preclinical studies are to determine a starting, safe dose for first-in-human study and assess potential toxicity of the product, which include new medical devices, prescription drugs, and diagnostics.
CT Imaging , Optical Imaging, Ultrasound Imaging, MRI Imaging and PET/SPECT Imaging among others are the different preclinical imaging products.
Growing number of clinical research organizations and pharmaceutical companies are the current trend in the preclinical imaging market.
The preclinical imaging market is projected to grow at a CAGR of 5.6% during the forecast period and is expected to reach US$ 3011.7 Mn by 2031.
Factors such as increased demand for imaging techniques and increase in preclinical research funding, by both private and public organizations boost the market growth.
The ultrasound imaging segment holds the highest CAGR in the preclinical imaging market during the forecast period.
The biotech companies segment dominated the preclinical imaging market in 2022.
Strict regulations in preclinical research restrict the market growth.
The COVID-19 pandemic had a positive impact on the preclinical imaging market due to the need to develop and test potential COVID-19 treatments and vaccines.
Technological advancements in molecular imaging creates a lucrative growth opportunity in the preclinical imaging market.
Type, product, application, end user and distribution channel are the different segments in the preclinical imaging market.
Some of the key players operating in the market are Siemens Healthineers, General Electric, Philips, Canon, FUJIFILM Holding, Carestream Health, Hitachi, Konica Minolta, Varex Imaging and Hologic among others.
Features | Type of License | |||
 Single User |   Multi User |  Corporate | ||
| e-Access | ✓ | ✓ | ✓ | |
User Sharing | 1 User Only | 2-6 Users | Unlimited within Company/Enterprise | |
⨉ | ⨉ | ✓ | ||
Free Customization | Up To 30 hrs work | Up To 60 hrs work | Up To 80 hrs work | |
Deliverable |
| ✓ | ✓ | ✓ |
| ⨉ | ✓ | ✓ | |
| ⨉ | ⨉ | ✓ | |
Analyst Support | 4 Month Post purchase | 7 Month Post purchase | One Year Post purchase | |
Free Report update in next update cycle | ⨉ | ⨉ | ✓ | |
Free Industry Update (Within 180 days) | ⨉ | ⨉ | ✓ | |
Benefit | Up to 20% off on next purchase | Up to 30% off on next purchase | Up to 40% off on next purchase | |
| Report ID: AA0423423 
